SCHEMBL603317

SCHEMBL603317

CN1CCN(C(=O)c2cc3sc(-c4ccccc4)cc3[nH]2)CC1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 19/20 0.65
CHEK1 O14757 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL603780 0.86 HRH4 (0.62) HRH4
SCHEMBL602659 0.81 HRH4 (0.65) HRH4CHEK1
SCHEMBL605299 0.79 HRH4 (1.00) HRH4
SCHEMBL69502 0.78 DAO (0.51)
SCHEMBL603362 0.77 HRH4 (1.00) HRH4
SCHEMBL604932 0.74 HRH4 (1.00) HRH4
SCHEMBL69116 0.73 HPGD (0.58)
SCHEMBL16599382 0.71 MAOB (0.51) HRH4
SCHEMBL605730 0.70 HRH4 (0.60) HRH4
SCHEMBL6130876 0.70 HRH4 (1.00) HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645758-B2 Heterocyclic compounds Janssen Pharmaceutica, N.Y. (BE) 2010-01-12 US claimed
US-20070185120-A1 Heterocyclic Compounds JANSSEN PHARMACEUTICA, N.V. 2007-08-09 US claimed
US-10195195-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2019-02-05 US disclosed
EP-3378476-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS Sensorion (FR) 2018-09-26 EP disclosed
US-9688989-B2 H4 receptor inhibitors for treating tinnitus SENSORION (FR) 2017-06-27 US disclosed
US-20170056397-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-03-02 US disclosed
EP-3130376-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-02-15 EP disclosed
US-9526725-B2 Selective histamine H4 receptor antagonists for the treatment of vestibular disorders INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2016-12-27 US disclosed
EP-2382013-B1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) 2016-07-13 EP disclosed
US-20150176010-A1 H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS SENSORION (FR) 2015-06-25 US disclosed
US-20120039913-A1 Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders INSERM (institut National de la Sante de la Recher Medicale) (FR) 2012-02-16 US disclosed
US-7645758-B2 Heterocyclic compounds Janssen Pharmaceutica, N.Y. (BE) 2010-01-12 US disclosed
US-20090069343-A1 Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus DUNFORD PAUL J 2009-03-12 US disclosed
US-20070185131-A1 Heterocyclic Compounds JANSSEN PHARMACEUTICA, N.V. 2007-08-09 US disclosed
US-20070185120-A1 Heterocyclic Compounds JANSSEN PHARMACEUTICA, N.V. 2007-08-09 US disclosed
US-7226938-B2 Heterocyclic compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2007-06-05 US disclosed
EP-1543011-B1 THIENOPYRROLYL AND FURANOPYRROLYL COMPOUNDS AND THEIR USE AS HISTAMINE H4 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2006-05-03 EP disclosed
EP-1543011-A2 THIENOPYRROLYL AND FURANOPYRROLYL COMPOUNDS AND THEIR USE AS HISTAMINE H4 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA N.V. (BE) 2005-06-22 EP disclosed
WO-2004022537-A2 THIENOPYRROLYL AND FURANOPYRROLYL COMPOUNDS AND THEIR USE AS HISTAMINE H4 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-18 WO disclosed
US-20040048878-A1 Cyclopentathienopyrroles and cyclopentafuranopyrroles for treating disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048878-A1 Cyclopentathienopyrroles and cyclopentafuranopyrroles for treating disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. HRH4, HRH2, HRH1 HRH4 1/4885CHEK1 3396/4885
US-20070185131-A1 Heterocyclic Compounds HRH4, HRH2, HRH1 HRH4 1/4885CHEK1 2117/4885
US-20090069343-A1 Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus HRH4, HRH2, HRH3 HRH4 1/4885CHEK1 1310/4885
US-20070185120-A1 Heterocyclic Compounds HRH4, HRH2, HRH1 HRH4 1/4885CHEK1 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.